Edwards Lifesciences (NYSE:EW) Price Target Raised to $95.00

Edwards Lifesciences (NYSE:EW) had its target price lifted by Truist Financial from $90.00 to $95.00 in a research report sent to investors on Thursday morning, MarketBeat.com reports. Truist Financial currently has a hold rating on the medical research company’s stock.

A number of other research firms have also recently commented on EW. Barclays reissued an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. BTIG Research lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Evercore reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Citigroup boosted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $98.95.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $85.72 on Thursday. The firm has a market cap of $49.36 billion, a PE ratio of 45.60, a PEG ratio of 2.15 and a beta of 0.86. The firm has a fifty day moving average of $87.34 and a 200 day moving average of $83.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. Edwards Lifesciences has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Activity

In related news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the sale, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Edwards Lifesciences by 27.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Edwards Lifesciences by 39.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock valued at $194,907,000 after acquiring an additional 648,870 shares during the last quarter. Central Pacific Bank Trust Division acquired a new stake in shares of Edwards Lifesciences during the fourth quarter valued at about $775,000. Sivik Global Healthcare LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $2,984,000. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.